Cleveland Clinic spinoff Tolera Therapeutics is more than halfway to its goal of a $1.65 million round of financing for its immunomodulation therapy for organ transplant. Cofounded by Dr. Maria Siemionow, the leader of the Cleveland Clinic surgery team that performed the nation’s first near-total face transplant in 2008, Tolera is developing a drug intended […]
Updated 4:36 p.m. Cleveland Clinic Innovations — the corporate venturing arm of the nation’s top heart hospital — is entering its second decade with a first-of-its-kind venture ranking, a brand-new incubator building and a growing portfolio of spin-out companies. Perhaps most impressive, those companies — 33 in all — have attracted more than $340 million […]
Cleveland Clinic spinoff Tolera Therapeutics Inc. has raised more than $4 million in equity to continue developing a drug that fights organ rejection in transplant patients, according to a regulatory filing with the Securities and Exchange Commission. The Series B funding will go toward a Phase 2 clinical trial of Tolera’s lead drug candidate, TOL101, […]
